pain therapy market

chronic pain

An illustration of a brain

The pain therapy market » Chronic pain

What does neuropathic mean?

PAIN IS A NEGATIVE FEELING associated with damage to the body’s tissues and it is crucial to survival. Putting a hand on a very hot object “feels bad” and that negative feeling rapidly teaches even very young children not to do that again. This sort of acute pain that resolves when the damage stops makes perfect evolutionary sense.

Sometimes, however, damage to the tissues, possibly from trauma or from some diseases (including viral infection, osteoarthritis and diabetes) results in pain that doesn’t go away and which becomes chronic. This has no survival value and, indeed, results in a real reduction in sufferers’ quality of life. Neuropathic pain is pain caused by any damage or disease affecting the sensory nervous system.

Allodynia is a distressing part of neuropathic pain and it is pain on the skin from something that shouldn’t be painful. Common in neuropathic pain states; shingles, diabetic neuropathy, physical injury to nerves, migraine and current treatments are ineffective. PN6047 blocks allodynia in animal models

Urgent need for new treatments

EXOGENOUS OPIOID compounds such as morphine are massively useful in combatting acute pain but they are much less effective versus chronic pain. Existing conventional opioids have important, possibly life threatening side effects (nausea, constipation, itching, respiratory depression) and patients quickly become tolerant to their analgesic effect necessitating increased doses with an increased risk of toxicity.

The euphoric effects of morphine like opioids means that they are used “recreationally” and this, along with their inappropriate prescribing for chronic pain states, has resulted in an epidemic of opioid overuse (particularly in the USA) leading to thousands of deaths and costing health services billions of dollars.

Chronic pain points

  • No survival value
  • Destroys quality of life
  • Affects 30%–50% of the world population
  • Current treatments (antidepressants / calcium channel blockers/opioids) relatively ineffective
  • Cost for prescription drugs in USA is > $18 p.a.
An illustration of a man having arm pain with arrows pointing to the brain

Latest news

View all
December 22, 2022

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

Read more
December 22, 2022

Seasons Greetings 2022

The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!

Read more
October 11, 2022

Strengthening the team

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

Read more
September 20, 2022

Good press in SvD

Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.

Read more

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Awesome 👌